...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!
Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials
Due Dilligence
Epigenetic Therapeutic Targets Summit, 7/15/2021: Clinical Development of the BET Bromodomain Inhibitor ZEN-3694
Posted by:
BearDownAZ
on
Jul 22, 2021 09:56AM
Triple Negative Breast Cancer Drug Development Digital Summit 4/29/2021
Posted by:
BearDownAZ
on
Jun 24, 2021 04:13PM
Zenith Epigenetics Links
AACR June 2020 Poster: Combination of ZEN-3694 with CDK4/6 inhibitors
Posted by:
BearDownAZ
on
Jun 29, 2020 07:24AM
Zenith AGM Corporate Update Slides
Also webcast available here: http://services.choruscall.ca/links/zenithagm20191031.html
Posted by:
BearDownAZ
on
Oct 31, 2019 09:04PM
Zenith Epigenetics Announces U.S. FDA Clearance of Investigational New Drug Application for ZEN-3694 in TNBC Program
Posted by:
BearDownAZ
on
Jun 06, 2019 01:07PM
The BET inhibitor ZEN-3694 Blocks Multiple Tumor Immune Suppressive Factors and Has the Potential to Increase the Efficacy of Anti-PD1 Treatment - Keystone 2019 Poster
Posted by:
BearDownAZ
on
Jun 06, 2019 01:06PM